Novo weight problems information sure for Eli Lilly and Amgen, says UBS – The Gentleman Report | World | Business | Science | Technology | Health
Today: Jul 25, 2025

Novo weight problems information sure for Eli Lilly and Amgen, says UBS

Novo weight problems information sure for Eli Lilly and Amgen, says UBS
December 22, 2024



UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Segment 3 topline weight problems information “underwhelmed,” a favorable read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema accomplished a mean weight lack of 20.4%, under Novo’s prior steerage of 25% and not so good as Lilly’s tirzepatide at a equivalent timepoint, the analyst tells traders in a analysis observe. UBS perspectives the CagriSema’s weight problems readout a favorable read-through to Lilly, “validating once more tirzepatide’s best-in-class profile.” It additionally perspectives Novo’s updates a favorable read-through to Amgen, announcing CagriSema’s efficacy now turns out most commonly in-line with MariTide, with most likely gastrointestinal intolerability problems, and may seem much less sexy with MariTide being a per 30 days titration routine. Printed first on TheFly – without equal supply for real-time, market-moving breaking monetary information. Check out Now>> See the highest shares beneficial through analysts >> Learn Extra on LLY:

OpenAI
Author: OpenAI

Don't Miss

Mosquitos in central Mass. the city take a look at certain for EEE

Mosquitos in central Mass. the city take a look at certain for EEE

Native Information It’s the first time this yr that the virus has
OpenAI and companions are construction a large AI knowledge middle in Texas

OpenAI and companions are construction a large AI knowledge middle in Texas

Stargate strikes ahead in spite of early skepticism When OpenAI introduced Stargate